To make disease-modifying first-in-class treatments available to patients suffering from conditions such as cancer, cognitive decline and fibrosis.
Medibiofarma discovers and develops new chemical entities (NCEs) with clinical proof-of-concept data in human patients
Medibiofarma focuses internal resources in the followings areas:
- Drug Design
- Medicinal and Synthetic Chemistry
- In Vitro Pharmacology
- Intellectual Property
- Clinical Trials
- Business Development
The remaining activities for the full characterization and nomination of a development candidate, such as in vivo pharmacology, toxicology and IND-enabling studies are carried out through partnerships with several companies (CROs), Research Centers and Universities.